NYSEHealth CareMedical - DevicesSnapshot 2026-08-31
Reading BSX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Cardiovascular segment grows at least 10% annually: Q2 FY26 total revenue +7.5% vs 10% target; Q3 FY26 guidance +3.0% to +5.0% vs 10% target.
Boston Scientific grows sales about 8% a year with strong cardiovascular gains. Profit margins stay near 13.5%. The company buys back stock and invests in new products. Recent earnings beats show execution despite challenges.
Product recalls and weaker outlook threaten sales growth. Guidance cuts and negative news create risks. Operational efficiency is mixed, pressuring profit margins and cash flow.
The price is about 44% below our fair value near $81. Analysts expect about 9% revenue growth. The market prices in risks from recent guidance cuts and product issues, which we partially agree with.
Breaks if: Cardiovascular segment growth falls below 7% next year
Breaks if: YoY revenue growth falls below 5% next year
No improvement in operational efficiency metrics over next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance despite some volatility in management execution.
The market seems to price in a neutral valuation with a slight expectation gap. BSX is considered cheap compared to its peers, but there is a premium built in, reflecting some investor caution.
Management is on track with priorities like driving net sales growth and expanding the cardiovascular segment. Recent financial performance has been strong, but there is a low probability of missing estimates, which could introduce risk.
The long-term thesis hinges on the performance of sector bellwethers and the potential for BSX to maintain or improve guidance. Additionally, any negative developments, such as litigation or a cut in guidance, could impact the outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat earnings expectations recently. This supports the view on net sales growth. However, management expects a decline in WATCHMAN revenue. They also face competitive pressure in Electrophysiology. This weakens the outlook for the cardiovascular segment.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Implement global restructuring programs to drive sustained cost efficiencies and support strategic priorities.
Breaks if: Operating margin falls below 12% next year
Overall, BSX's fundamentals are solid, but the elevated risks and sector dynamics warrant close monitoring. Not investment advice.
